Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

4(66.7%)

Phase 1

2(33.3%)

6Total

Phase 2(4)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT01893801Phase 1Completed

Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA

Role: lead

NCT03392571Phase 2Withdrawn

Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients

Role: lead

NCT03634332Phase 2Unknown

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

Role: lead

NCT02781012Unknown

Project Survival-Prospective Biomarker Discovery

Role: lead

NCT01488552Phase 1Completed

Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

Role: lead

NCT01298011Phase 2Completed

Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer

Role: lead

NCT00296114Completed

Pancreatic Cancer Serum and DNA Repository

Role: lead

NCT00226005Phase 2Completed

PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma

Role: lead

All 8 trials loaded